Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy

Archives of Internal Medicine

Volumn 169, Issue 17, 2009, Pages 1587-1594

  Weinberg, Joy M ^a   Appel, Lawrence J ^b   Bakris, George ^c   Gassman, Jennifer J ^d   Greene, Tom ^d   Kendrick, Cynthia A ^d   Wang, Xuelei ^d   Lash, James ^e   Lewis, Julia A ^f   Pogue, Velvie ^g   Thornley Brown, Denyse ^h   Phillips, Robert A ⁱ  

^a LENOX HILL HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g HARLEM HOSPITAL CENTER   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL SUCCINATE; POTASSIUM; RAMIPRIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; HYPERKALEMIA; HYPERTENSION; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME VARIABLE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AFRICAN AMERICANS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; POTASSIUM; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349765136     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.284     Document Type: Article

References (24)

1. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857-1863.
2. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73-87. (Pubitemid 32661190)
3. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial: Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN): Ramipril Efficacy in Nephropathy. Lancet. 1998;352(9136):1252-1256.
4. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354(2):131-140. (Pubitemid 43076710)
5. Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension. 1979;1(3):274-280.
6. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med. 1998;158(1):26-32.
7. Hannedouche T, Landais P, Goldfarb B, et al. Randomised controlled trial of enalapril and β-blockers in non-diabetic chronic renal failure. BMJ. 1994;309(6958): 833-837. (Pubitemid 24305005)
8. Bakris GL, Siomos M, Richardson D, et al; VAL-K Study Group. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int. 2000;58(5):2084-2092. (Pubitemid 30807937)
9. Mangrum AJ, Bakris G. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004;24(2):168-175. (Pubitemid 38387858)
10. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983;309(23):1414-1419.
11. Vincent HH, Man in 't Veld AJ, Boomsma F, Derkx FH, Wenting GJ, Schalekamp MA. Cardioprotection by blockade of beta 2-adrenoceptors. Eur Heart J. 1983; 4(suppl D):109-115.
12. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-2431.
13. Agodoa LY, Appel L, Bakris GL, et al; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719-2728.
14. Reams GP, Bauer JH. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med. 1986;146 (11):2145-2148.
15. Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med. 1982;73(5):719-725.
16. Suki WN. Disposition and regulation of body potassium: an overview. Am J Med Sci. 1976;272(1):31-41.
17. Singer J, Willet J. Extending the discrete-time hazard model. In: Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York, NY: Oxford University Press; 2003:407-467.
18. Gennari FJ, Segal AS. Hyperkalemia: an adaptive response in chronic renal insufficiency. Kidney Int. 2002;62(1):1-9. (Pubitemid 34754042)
19. Wieczorowska-Tobis K, Niemir Z, Guzik P, Breborowicz A, Oreopoulos D. Difference in estimated GFR with two different formulas in elderly individuals. Int Urol Nephrol. 2006;38(2):381-385. (Pubitemid 44138171)
20. Michelis MF. Hyperkalemia in the elderly. Am J Kidney Dis. 1990;16(4):296-299.
21. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol. 1993;33:435-465. (Pubitemid 23116014)
22. Howes LG. Which drugs affect potassium. Drug Saf. 1995;12(4):240-244.
23. Keilani T, Danesh FR, Schlueter WA, Molteni A, Batlle D. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis. 1999;33(3):450-457. (Pubitemid 29107021)
24. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000; 160(5):685-693.